Zofran (Ondasetron): Difference between revisions

No edit summary
Tag: Reverted
No edit summary
Tags: Manual revert Visual edit
 
(42 intermediate revisions by 2 users not shown)
Line 3: Line 3:
[[Category:5-HT3]]
[[Category:5-HT3]]


 
{{infobox drug
{{Infobox
| drug_name = zofranx
| Drug_name = Zofran
| image = zofran.png
| IUPAC_name = (RS)-1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one
| caption = zofran 4 mg tablet
| Image = Zofran.png
| type = antiemetic
| Caption = Zofran 4 mg tablet
| used_for = prevention of nausea and vomiting
| Type = Antiemetic
| atc_code = A04AA01
| Used_for = Prevention of nausea and vomiting
| legal_status = prescription only
| ATC_code = A04AA01
| routes_of_administration = oral, intravenous, intramuscular
| Legal_status = Prescription only
| bioavailability = sss
| Routes_of_administration = Oral, intravenous, intramuscular
| protein_bound = 70-76%
| Bioavailability = 58% (Oral)
| metabolism = liver (CYP2D6, CYP3A4)
| Protein_bound = 70-76%
| elimination_half-life = 3-6 hours
| Metabolism = Liver (CYP2D6, CYP3A4)
| excretion = kidney (60%), feces (40%)
| Elimination_half-life = 3-6 hours
| Excretion = Kidney (60%), feces (40%)
| CAS_number = 99614-02-5
| PubChem = 43815
}}
}}


Line 74: Line 70:
* {{RxList|Zofran}}
* {{RxList|Zofran}}
* {{MedlinePlus|a601209}}
* {{MedlinePlus|a601209}}


[[Category:5-HT3 antagonists]]
[[Category:5-HT3 antagonists]]

Latest revision as of 22:39, 17 May 2023



Zofran (ondansetron) is an antiemetic medication used to prevent nausea and vomiting, particularly in the field of anesthesia. It is a selective 5-HT3 receptor antagonist, which works by blocking the action of serotonin in the brain and the gastrointestinal tract.

Zofran (Ondasetron)






















































































































































drug name: zofranx
image: zofran.png
caption: zofran 4 mg tablet
type: antiemetic
routes of administration: oral, intravenous, intramuscular
metabolism: liver (CYP2D6, CYP3A4)
legal status: prescription only
bioavailability: sss
protein bound: 70-76%
elimination half-life: 3-6 hours
excretion: kidney (60%), feces (40%)

Route of administration

  • Oral: Disintegrating tablets, film-coated tablets, and oral solution
  • Intravenous: Injection
  • Intramuscular: Injection

Dose

For anesthesia-related nausea and vomiting:

  • Adult:
 * Oral: 16 mg before anesthesia induction
 * Intravenous: 4 mg before anesthesia induction or immediately before/during/after surgery
  • Pediatric:
 * Oral: 4 mg for children aged 4-11 years, 30-60 minutes before surgery
 * Intravenous: 0.1 mg/kg (up to 4 mg) for children aged 1 month-12 years, immediately before/during/after surgery

Half-life

  • The elimination half-life of ondansetron is approximately 3-6 hours.

Expected time to work

  • Oral: Onset of action is approximately 30 minutes to 2 hours.
  • Intravenous: Onset of action is approximately 5-30 minutes.

Use in anesthesia

Zofran is commonly used in anesthesia to:

  • Prevent postoperative nausea and vomiting (PONV)
  • Prevent nausea and vomiting induced by chemotherapy
  • Prevent nausea and vomiting associated with radiation therapy

Side effects

  • Headache
  • Fatigue
  • Constipation
  • Diarrhea
  • Dizziness

Contraindications

  • Hypersensitivity to ondansetron or any component of the formulation
  • Concomitant use with apomorphine
  • Patients with congenital long QT syndrome

Drug interactions

References


External links